RSSStudy shows pandemic H1N1 can fail to respond to antiviral drugs
Michael Haltman | March 27, 2010
Studies Conducted By The National Institute of Allergy and Infectious Diseases (NIAID) and the US Food and Drug Administration (FDA)
The study, to be released in Clinical Infectious Diseases (CID), reports that "that even a short course of oseltamivir (Tamiflu) can lead to antiviral resistance and that patients can develop resistance to peramivir, an alternative to oseltamivir in emergency situations."
The study results point out the need for the rapid development of new antiviral drugs that can fight the infection. The name of the genetic mutation found in some flu strains which has proven drug resistant is H275Y.
Said Dr. Matthew Memoli, co-head of the research team, "...but these cases of rapid appearance of drug-resistant 2009 H1N1 influenza in immune-compromised patients are worrisome and should prompt clinicians to reconsider how they use available flu drugs...As clinicians, we should carefully consider our treatment options and use all the drugs available to us wisely, This is especially important in a patient with prolonged infection or when an antiviral drug fails to cure the patient after the recommended course of treatment."
According to the World Health Organization, 267 cases of Tamiflu-resistant H1N1 have been reported since the pandemic started last year.
The study will be out in the May 1 edition of CID.
Photo courtesy of Canada.com
From the Examiner.
Contributor's website: http://politicsandfinance.blogspot.com/
Content posted by users from other sites is posted for commentary and news purposes under fair use and each author is responsible for their own postings and a particular posting should not be construed as being endorsed by this site or its owner.
Leave a Reply
Loading ...Recommended Reading:
